Phase III cardiovascular outcome study.
Enrolling over 22,500 patients in 800 clinical centers worldwide. CRU site was the worldwide best enroller with 177 randomized patients. The sponsor was able to submit the study results to the FDA on time and got market authorization just before all other competitors. The site was audited by the sponsor: neither critical nor major findings, and also inspected by FDA after study completion with NAI result.